Global cardiomyopathy market is anticipated to grow at a CAGR of 8.3% during the forecast period (2024–2031). Cardiomyopathy refers to a heart disease that causes hindrances in pumping blood to the rest of the body. It can also lead to some other serious heart conditions. Common causes of cardiopathy include autoimmune diseases, infections, endocrine diseases, neuromuscular disorders, nutritional deficiency, and over-exposure to toxins such as alcohol. The market growth is driven by the advancements in understanding and managing cardiomyopathy and a rise in incidences of congestive heart failure, coronary heart disease, and heart attack.
Get Free Sample link @ https://www.omrglobal.com/request-sample/cardiomyopathy-market
Recent Developments
- In June 2024, Alnylam Pharmacuticals, Inc. announced positive topline results from the HELIOS-B Phase 3 study of Vutrisiran. It achieved 28.0% and 33.0% reduction in composite mortality and recurrent cardiovascular events in the overall and monotherapy populations.
- In March 2023, Ionics Pharmaceuticals, Inc. announced the evaluation of Eplontersen for CARDIO-TTRansform Phase III trial for transthyretin-mediated amyloid cardiomyopathy, a systemic, progressive, and fatal condition that typically leads to progressive heart failure and often mortality within three to five years from disease onset.
Full report of Cardiomyopathy Market available @ https://www.omrglobal.com/industry-reports/cardiomyopathy-market
Market Coverage
- The market number available for 2023-2031
- Base year: 2023
- Forecast period: 2024-2031
- Segment Covered-
o By Type
o By Diagnosis Test
o By Treatment
o By End-user
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Amgen Inc., Bristol-Myers Squibb (BMS), Merck Group, Novartis Pharma AG, and Pfizer Inc. among others.
Key questions addressed by the report
- What is the market’s growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Cardiomyopathy Market Report Segment
By Type
- Dilated Cardiomyopathy
- Restrictive Cardiomyopathy
- Unclassified Cardiomyopathy
- Hypertrophic Cardiomyopathy
- Arrhythmogenic Right Ventricular Dysplasia
By Diagnosis Test
- Blood Tests
- Cardiac MRI
- Chest X-Ray
- Cardiac CT scan
- Echocardiogram
- Treadmill Stress Test
- Electrocardiogram (ECG)
- Cardiac Catheterization
- Genetic Testing or Screening
By Treatment
- Medication
- Surgically Implanted Devices
- Nonsurgical Procedures
- Septal Ablation
- Radiofrequency Ablation
- Surgery
- Septal Myectomy
- Heart Transplant
By End-user
- Homecare
- Hospitals and Clinics
- Diagnostic Center
- Other (Ambulatory Surgical Centers (ASCs)
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/cardiomyopathy-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
